Is KLRA or SRZN more profitable?

Kailera Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Surrozen -2,885.33% N/A -93.62%

Does the media favor KLRA or SRZN?

In the previous week, Surrozen had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 12 mentions for Surrozen and 10 mentions for Kailera Therapeutics. Surrozen's average media sentiment score of 0.58 beat Kailera Therapeutics' score of 0.28 indicating that Surrozen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Surrozen 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ORIC or SRZN?

In the previous week, Surrozen had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 12 mentions for Surrozen and 11 mentions for Oric Pharmaceuticals. Surrozen's average media sentiment score of 0.58 beat Oric Pharmaceuticals' score of 0.35 indicating that Surrozen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Surrozen 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, OMER or SRZN?

Omeros has higher earnings, but lower revenue than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 14.77 Surrozen $3.48M 97.18 -$242.03M -$40.55 N/A

Is OMER or SRZN more profitable?

Omeros has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Surrozen -2,885.33% N/A -93.62%

Does the media refer more to OMER or SRZN?

In the previous week, Surrozen had 7 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Surrozen and 5 mentions for Omeros. Surrozen's average media sentiment score of 0.58 beat Omeros' score of 0.40 indicating that Surrozen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Surrozen 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, SRZN or KARD?

Kardigan has lower revenue, but higher earnings than Surrozen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Surrozen $3.48M 97.18 -$242.03M -$40.55 N/A Kardigan N/A N/A -$191.94M N/A N/A

Is SRZN or KARD more profitable?

Kardigan has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Company Net Margins Return on Equity Return on Assets Surrozen -2,885.33% N/A -93.62% Kardigan N/A N/A N/A

Does the media prefer SRZN or KARD?

In the previous week, Surrozen had 6 more articles in the media than Kardigan. MarketBeat recorded 12 mentions for Surrozen and 6 mentions for Kardigan. Surrozen's average media sentiment score of 0.58 beat Kardigan's score of 0.10 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Surrozen (SRZN) Competitors

$29.13 -0.19 (-0.65%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$29.17 +0.04 (+0.14%)

As of 10/5/2026 07:44 PM Eastern

Compare

SRZN vs. KLRA, ORIC, OMER, KARD, and DMRA

Should you buy Surrozen stock or one of its competitors? Surrozen's main competitors and comparable companies include Kailera Therapeutics (KLRA), Oric Pharmaceuticals (ORIC), Omeros (OMER), Kardigan (KARD), and Damora Therapeutics, Inc. Common Stock (DMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Surrozen compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Kailera Therapeutics has higher earnings, but lower revenue than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Surrozen	$3.48M	97.18	-$242.03M	-$40.55	N/A

In the previous week, Surrozen had 2 more articles in the media than Kailera Therapeutics. MarketBeat recorded 12 mentions for Surrozen and 10 mentions for Kailera Therapeutics. Surrozen's average media sentiment score of 0.58 beat Kailera Therapeutics' score of 0.28 indicating that Surrozen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Surrozen	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Surrozen	-2,885.33%	N/A	-93.62%

66.6% of Surrozen shares are held by institutional investors. 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kailera Therapeutics presently has a consensus target price of $42.75, indicating a potential upside of 294.37%. Surrozen has a consensus target price of $48.33, indicating a potential upside of 65.92%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Kailera Therapeutics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Kailera Therapeutics beats Surrozen on 7 of the 13 factors compared between the two stocks.

How does Surrozen compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Oric Pharmaceuticals presently has a consensus price target of $20.67, indicating a potential upside of 65.47%. Surrozen has a consensus price target of $48.33, indicating a potential upside of 65.92%. Given Surrozen's higher probable upside, analysts clearly believe Surrozen is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Oric Pharmaceuticals has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Oric Pharmaceuticals has higher earnings, but lower revenue than Surrozen. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Surrozen	$3.48M	97.18	-$242.03M	-$40.55	N/A

In the previous week, Surrozen had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 12 mentions for Surrozen and 11 mentions for Oric Pharmaceuticals. Surrozen's average media sentiment score of 0.58 beat Oric Pharmaceuticals' score of 0.35 indicating that Surrozen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Surrozen	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Surrozen	-2,885.33%	N/A	-93.62%

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 31.7% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Oric Pharmaceuticals and Surrozen tied by winning 8 of the 16 factors compared between the two stocks.

How does Surrozen compare to Omeros?

Omeros (NASDAQ:OMER) and Surrozen (NASDAQ:SRZN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Omeros has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Surrozen	-2,885.33%	N/A	-93.62%

Omeros has higher earnings, but lower revenue than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.77
Surrozen	$3.48M	97.18	-$242.03M	-$40.55	N/A

48.8% of Omeros shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Omeros currently has a consensus target price of $34.00, indicating a potential upside of 79.89%. Surrozen has a consensus target price of $48.33, indicating a potential upside of 65.92%. Given Omeros' higher possible upside, analysts plainly believe Omeros is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Omeros has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

In the previous week, Surrozen had 7 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Surrozen and 5 mentions for Omeros. Surrozen's average media sentiment score of 0.58 beat Omeros' score of 0.40 indicating that Surrozen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Surrozen	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omeros and Surrozen tied by winning 7 of the 14 factors compared between the two stocks.

How does Surrozen compare to Kardigan?

Surrozen (NASDAQ:SRZN) and Kardigan (NASDAQ:KARD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

In the previous week, Surrozen had 6 more articles in the media than Kardigan. MarketBeat recorded 12 mentions for Surrozen and 6 mentions for Kardigan. Surrozen's average media sentiment score of 0.58 beat Kardigan's score of 0.10 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kardigan has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Kardigan	N/A	N/A	N/A

Surrozen presently has a consensus price target of $48.33, indicating a potential upside of 65.92%. Kardigan has a consensus price target of $42.25, indicating a potential upside of 177.23%. Given Kardigan's higher possible upside, analysts plainly believe Kardigan is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kardigan has lower revenue, but higher earnings than Surrozen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	97.18	-$242.03M	-$40.55	N/A
Kardigan	N/A	N/A	-$191.94M	N/A	N/A

Summary

Surrozen beats Kardigan on 7 of the 11 factors compared between the two stocks.

How does Surrozen compare to Damora Therapeutics, Inc. Common Stock?

Surrozen (NASDAQ:SRZN) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Surrozen presently has a consensus target price of $48.33, suggesting a potential upside of 65.92%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $46.50, suggesting a potential upside of 129.97%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Surrozen had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 12 mentions for Surrozen and 11 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.59 beat Surrozen's score of 0.58 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Damora Therapeutics, Inc. Common Stock has lower revenue, but higher earnings than Surrozen. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	97.18	-$242.03M	-$40.55	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A

Surrozen has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Surrozen's return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Damora Therapeutics, Inc. Common Stock beats Surrozen on 10 of the 16 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$340.42M	$3.85B	$7.15B	$13.26B
Dividend Yield	N/A	3.65%	2.53%	17.36%
P/E Ratio	-0.72	12.99	274.34	26.20
Price / Sales	97.18	1,333.35	619.11	92.00
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	-1.52	17.06	11.23	6.40
Net Income	-$242.03M	-$23.20M	$3.49B	$381.07M
7 Day Performance	-8.91%	-2.14%	-1.31%	-0.28%
1 Month Performance	27.99%	-10.22%	-5.97%	-4.51%
1 Year Performance	110.48%	17.47%	7.26%	1.63%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	2.8065 of 5 stars	$29.13 -0.6%	$48.33 +65.9%	+116.5%	$340.42M	$3.48M	N/A	44
KLRA Kailera Therapeutics	2.5219 of 5 stars	$11.29 +2.7%	$42.75 +278.7%	N/A	$1.46B	N/A	N/A	145
ORIC Oric Pharmaceuticals	2.2775 of 5 stars	$13.70 +2.4%	$20.18 +47.4%	+8.0%	$1.41B	N/A	N/A	111	Analyst Forecast
OMER Omeros	3.7591 of 5 stars	$19.14 -0.6%	$34.00 +77.7%	+312.7%	$1.38B	$38.42M	14.94	175
KARD Kardigan	3.1958 of 5 stars	$14.79 +0.9%	$42.25 +185.7%	N/A	$1.38B	N/A	N/A	241	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. KLRA, ORIC, OMER, KARD, and DMRA

How does Surrozen compare to Kailera Therapeutics?

Summary

How does Surrozen compare to Oric Pharmaceuticals?

Summary

How does Surrozen compare to Omeros?

Summary

How does Surrozen compare to Kardigan?

Summary

How does Surrozen compare to Damora Therapeutics, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. KLRA, ORIC, OMER, KARD, and DMRA

How does Surrozen compare to Kailera Therapeutics?

Which has stronger earnings & valuation, KLRA or SRZN?

Does the media favor KLRA or SRZN?

Is KLRA or SRZN more profitable?

Do insiders and institutionals believe in KLRA or SRZN?

Do analysts prefer KLRA or SRZN?

Summary

How does Surrozen compare to Oric Pharmaceuticals?

Do analysts prefer ORIC or SRZN?

Which has more volatility and risk, ORIC or SRZN?

Which has higher earnings and valuation, ORIC or SRZN?

Does the media refer more to ORIC or SRZN?

Is ORIC or SRZN more profitable?

Do institutionals and insiders believe in ORIC or SRZN?

Summary

How does Surrozen compare to Omeros?

Is OMER or SRZN more profitable?

Which has stronger valuation and earnings, OMER or SRZN?

Do insiders and institutionals believe in OMER or SRZN?

Do analysts recommend OMER or SRZN?

Which has more volatility & risk, OMER or SRZN?

Does the media refer more to OMER or SRZN?

Summary

How does Surrozen compare to Kardigan?

Does the media prefer SRZN or KARD?

Is SRZN or KARD more profitable?

Do analysts rate SRZN or KARD?

Do institutionals & insiders believe in SRZN or KARD?

Which has preferable earnings & valuation, SRZN or KARD?

Summary

How does Surrozen compare to Damora Therapeutics, Inc. Common Stock?

Do analysts prefer SRZN or DMRA?

Does the media favor SRZN or DMRA?

Which has preferable valuation and earnings, SRZN or DMRA?

Which has more volatility & risk, SRZN or DMRA?

Is SRZN or DMRA more profitable?

Do institutionals & insiders hold more shares of SRZN or DMRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools